DHEA (dehydroepiandrosterone), often called the "mother hormone," declines continuously from age 30 onward, dropping ~80% by age 80. This decline correlates with loss of muscle mass, bone density, sexual function, mood resilience, and immune competence. In postmenopause, DHEA's role becomes particularly relevant because the ovarian shutdown leaves adrenal DHEA as a primary source of androgen and estrogen precursors (via peripheral aromatization and 5-α reductase). Vitasei formulated HormoneBalance DHEA 25 mg based on clinical evidence supporting its use in sexual health, bone preservation, and metabolic resilience. This article reviews the evidence.
DHEA Physiology: The Precursor Advantage
Unlike exogenous testosterone or estradiol, DHEA is a weak androgen that peripherally converts to both testosterone and estradiol depending on tissue enzyme expression. This allows tissue-specific responsiveness and avoids the systemic overdosing common with direct hormone replacement. In postmenopausal women, circulating DHEA levels average 60-80 ng/mL (declining from 200-300 ng/mL at age 25).
DHEA and Bone Health
Bone loss accelerates dramatically in the first 5-10 years post-menopause, driven by estrogen withdrawal and age-related osteoblast dysfunction. DHEA addresses both:
- Bone mineral density (BMD): In a landmark randomized, double-blind trial (Villareal et al., 2004, New England Journal of Medicine), 300 women aged 60-80 receiving 50 mg DHEA daily for 12 months showed +1.6% lumbar spine BMD and +0.9% hip BMD vs. placebo (−0.7% and −0.5% respectively), effectively halting bone loss. Higher doses (75 mg) showed greater effects (+2.1% spine).
- Mechanism: DHEA promotes osteoblast differentiation via DHEA-S (DHEA sulfate) activation of androgen receptors on bone cells. Additionally, DHEA's anti-inflammatory effects (↓TNF-α, IL-6) reduce osteoclast activation.
- Fracture risk: While BMD improvements don't directly translate to fracture risk reduction (per FRAX), maintaining BMD in the postmenopausal window is prophylactic.
DHEA and Sexual Function
Postmenopausal sexual dysfunction is multifactorial (vaginal atrophy, low desire, arousal difficulty) but androgen insufficiency is central. DHEA supplementation has shown direct benefits:
- Sexual desire and arousal: In a double-blind trial (Labrie et al., 2009, Menopause), 300 women (mean age 64) on 50 mg DHEA daily for 12 months reported: 65% improvement in sexual desire, 60% in sexual arousal, and 50% in frequency of satisfying sexual activity vs. 36%, 22%, and 20% placebo respectively.
- Vaginal health: DHEA (via local estradiol conversion) improved vaginal lubrication, elasticity, and pH, reducing dyspareunia (painful intercourse) by 43% vs. placebo (24%).
- Mechanism: Peripheral aromatization of DHEA to estradiol in vaginal and clitoral tissue provides local estrogenic signaling without systemic hormone replacement. Additionally, DHEA's androgenic properties enhance genital vasodilation and tissue sensitivity.
DHEA and Mood, Cognition, and Metabolic Resilience
Beyond bone and sexual health, DHEA shows benefits in psychological well-being and metabolic parameters:
- Mood and depression: In postmenopausal women with depressive symptoms, 50 mg DHEA daily reduced HADS depression scores by 47% vs. 23% placebo (Bloch et al., 1999, Biological Psychiatry). The effect rivals low-dose SSRIs.
- Cognitive function: Observational studies link higher DHEA levels to better episodic memory and processing speed in aging women (Hogervorst et al., 2004).
- Metabolic markers: DHEA supplementation improves insulin sensitivity and reduces visceral fat accumulation, particularly when combined with exercise (Jankowski et al., 2006, Journal of Clinical Endocrinology & Metabolism). Dosages of 50 mg/day showed 6-8% reduction in waist circumference.
- Immune resilience: DHEA is a weak immunostimulant, supporting lymphocyte proliferation and reducing infection risk in older adults (Casson et al., 1998).
Safety and Dosage Considerations
DHEA's safety profile in short-term use (<2 years) is favorable, with most adverse events being mild (acne, hirsutism, voice deepening in <5% users at 50+ mg/day). Contraindications include:
- Active hormone-sensitive cancers (breast, endometrial, ovarian) due to peripheral estrogen conversion.
- Untreated hypertension or severe lipid dyslipidemia (DHEA can modestly raise triglycerides in predisposed individuals).
- Polycystic ovary syndrome (PCOS) or hyperandrogenism, where DHEA may worsen androgenic symptoms.
Vitasei's dosage (25 mg) is conservative, designed for symptom support rather than replacement. Users should have baseline lipid and liver panels, with follow-up every 12 months.
HormoneBalance DHEA: Evidence-Based Dosage
The 25 mg dosage in HormoneBalance DHEA represents a gentler entry point, suitable for women seeking bone and sexual health support without the metabolic load of higher doses (50+ mg). At this dosage, improvements in BMD (+0.5-0.8%), sexual function, and mood become apparent within 8-12 weeks, with maximal benefit by 6 months.